Bharat Parenterals gets DCGI nod for favipiravir oral suspension for Covid-19 patientsFavipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections
Last Updated IST
Tablets of Avigan (generic name : Favipiravir). Credit: Reuters Photo
Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.